Pirche and Natera announced a collaboration to connect pre-transplant risk stratification with post-transplant monitoring for transplant patients. Under the agreement, Pirche will pair its TxPredictor platform and pre-treatment immunologic risk scores with Natera’s Prospera dd-cfDNA test results. The goal is to give transplant teams an integrated view of immune status across the transplant journey, with Pirche planning education for customers on using TxPredictor alongside Prospera. The effort begins at the 2026 American Transplant Congress, aiming to support more individualized immunosuppression decisions. Terms of the deal were not disclosed, but the partnership signals ongoing efforts to combine algorithmic risk prediction with molecular monitoring tools in real-world transplant management workflows.